Last mentioned: Feb 27, 2026
EU Regulatory Milestone
Crinetics receives positive CHMP opinion for Palsonify in the European Union.
Crinetics Capital Raise
Public offering brings Crinetics' total liquidity to approximately $1.4B.
NVIDIA Reference Status
Aeva 4D LiDAR selected as reference sensor for NVIDIA DRIVE Hyperion.
Palsonify Launch
Crinetics initiates U.S. commercial launch of Palsonify for acromegaly.
A wave of Q4 2025 earnings reports highlights a pivotal shift for growth-stage technology and biotech firms as they transition from R&D to commercial scaling. Crinetics and Aeva Technologies emerged as standout performers, securing massive cash reserves and tier-one partnerships that validate their long-term market positions.
The fourth quarter of 2025 highlighted a critical divide in the industrial supply chain, with advanced materials and sensor manufacturers successfully scaling production while retail and IoT sectors faced significant margin pressure from tariffs and inventory imbalances. Strategic shifts toward diversified procurement and high-value technology partnerships are now defining the competitive landscape for 2026.
The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.